PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Stephen Nicholls, FRACP, FACC, FESC, FAHA
- MinuteCE®
Understanding the role of triglycerides in the assessment of residual risk
0.50 program creditsProf. Alberto Zambon MD, PhD, FAHA
John Kastelein, MD, PhD
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Erin D. Michos, MD, MHS, FACC, FAHA, FASE